Marty Makary resigned as commissioner of the Food and Drug Administration on Tuesday, ending a roughly four-month tenure that was widely described as uneven and turbulent. Multiple outlets confirmed his departure, with some reporting he intended to resign and others suggesting he was effectively forced out amid broader upheaval at the agency.

Makary, a Johns Hopkins surgeon and author who was nominated by President Trump, took over the FDA at the start of the administration with a stated goal of cutting bureaucratic inefficiency. His time at the helm was complicated by controversies over regulatory decisions, staffing instability, and policy disputes involving issues ranging from flavored vaping products to mifepristone access.

The circumstances surrounding his exit were disputed. Breitbart and Axios reported that his resignation came amid reports of a potential firing, suggesting White House pressure played a role. ABC News cited sources saying Makary intended to resign, framing the departure as a personal decision. The distinction reflects broader uncertainty about the administration's relationship with the agency during his leadership.

The FDA has faced significant institutional strain in recent months, including staff reductions tied to the broader federal workforce reorganization and ongoing scrutiny of its drug and food safety operations. Makary's departure adds further instability to an agency whose leadership is considered critical to public health oversight.

No immediate successor has been named. The resignation raises questions about continuity at the FDA at a time when the agency is managing multiple high-profile regulatory and policy challenges.